BK VIRUS (BK Polyoma virus) - Qualitative

The quantitative test is real-time PCR for BK virus DNA, usually performed on plasma or whole blood (urine can be tested for viruria). Results report viral load in copies/mL (or IU/mL) to monitor viremia and guide transplant management. Persistent plasma loads above about 10,000 copies/mL (10^4) raise concern for BK-associated nephropathy and may prompt treatment changes.

BK polyomavirus is a common virus usually acquired in childhood that remains latent in the urinary tract. It’s typically harmless in healthy people but can reactivate in immunocompromised patients—especially kidney or hematopoietic stem cell transplant recipients—causing BK virus nephropathy or hemorrhagic cystitis. Diagnosis uses urine/plasma PCR; treatment focuses on reducing immunosuppression and supportive measures, as specific antiviral options are limited.

Polyomaviruses usually cause mild or silent infections in healthy people and often remain latent. They can be serious in immunocompromised individuals: JC virus may cause progressive multifocal leukoencephalopathy (PML), BK virus can damage transplanted kidneys or cause hemorrhagic cystitis, and Merkel cell polyomavirus is linked to a rare skin cancer. Risk and care depend on immune status and medical evaluation.

BK virus is usually harmless in healthy people but can be serious in immunocompromised patients. In kidney-transplant recipients it can cause BK nephropathy leading to kidney dysfunction or graft loss; in bone-marrow transplant patients it may cause hemorrhagic cystitis. Diagnosis relies on urine/blood PCR and kidney biopsy; treatment is mainly reducing immunosuppression and supportive care, requiring specialist monitoring.

Yes. BK virus commonly causes urinary shedding (BK viruria), especially in immunocompromised people and kidney transplant recipients. It’s detected by urine PCR and may produce “decoy cells” on urine cytology. Most infections are asymptomatic, but high-level viruria can precede BK viremia and BK virus–associated nephropathy, requiring monitoring and management to protect graft function.

HBV DNA is reported in IU/mL. Undetectable levels are typically below assay limits (often <20 IU/mL). Clinically, <2,000 IU/mL is considered a low viral load, 2,000–20,000 IU/mL indicates active replication and may warrant monitoring or treatment depending on ALT and fibrosis, and >20,000 IU/mL is high, associated with greater risk of liver damage and likely need for antiviral therapy.